search icon

    Market Snapshot

    • S&P Futures

      3,914.75

    • Dow Futures

      31,478

    • Nasdaq Futures

      12,132.75

    blog search icon

    ADC Therapeutics SA

    (NYSE:ADCT)

    $6.88

    $0.32

    4.88%

    ADC Therapeutics SA Chart

    ADCT Stock Price Today

    ADC Therapeutics SA (ADCT) stock rallied over 4.88% intraday to trade at $6.88 a share on NYSE. The stock opened with a gain of 3.30% at $6.64 and touched an intraday high of $6.9, rising 4.88% against the last close of $6.56. The stock went to a low of $6.56 during the session.

    Stock Snapshot

    $6.56

    Prev. Close

    495.98 Million

    Market Cap

    $6.56

    Day Low

    $6.64

    Open

    76.82 Million

    Number of Shares

    $6.9

    Day High

    -

    P/E ratio

    -2.54

    EPS (TTM)

    6.07

    Cash Flow per Share

    15.73

    Free Float in %

    2.44

    Book Value

    384,840

    Volume

    ADC Therapeutics SA Historical Data

    DateOpenHighLowCloseVolume
    2022-06-23$6.64$6.9$6.56$6.88384,800
    2022-06-22$6.66$6.96$6.5$6.56416,500
    2022-06-21$6.51$7.01$6.3$6.78407,800
    2022-06-17$6.05$6.53$6.05$6.35624,600
    2022-06-16$5.84$6.025$5.52$5.96353,900
    2022-06-15$6.09$6.29$6.035$6.05175,900
    2022-06-14$6.33$6.49$5.99$6.07555,500
    2022-06-13$6.47$6.65$6.002$6.3223,500
    2022-06-10$6.8$7.01$6.41$6.67398,400
    2022-06-09$7.24$7.24$6.99$7172,100

    Contact Details

    Biopole
    Route de la Corniche 3B
    Epalinges 1066
    Switzerland

    Webiste:ADCT

    41 21 653 02 00

    Company Information

    Employees-

    Beta-

    Sales or Revenue33.92 Million

    5Y Sales Change-

    Fiscal Year Ends2021-12-30

    SectorHealth Care

    IndustryBiotechnology

    About Company

    ADC Therapeutics SA, a commercial-stage biotechnology company, develops antibody drug conjugates (ADC) for patients suffering from hematological malignancies and solid tumors. Its flagship product ZYNLONTA that is in Phase II clinical trial for the treatment of relapsed or refractory diffuse large B-cell lymphoma (DLBCL) and follicular lymphoma; Phase III clinical trial in combination with rituximab to treat relapsed or refractory DLBCL in second-line transplant-ineligible patients; and Phase I clinical trial for treatment of relapsed or refractory non-hodgkin lymphoma (NHL). The company is also developing camidanlumab tesirine, an ADC that has completed Phase I clinical trial to treat relapsed or refractory NHL; in Phase II clinical trial in relapsed or refractory hodgkin lymphoma; and in Phase Ib clinical trial for selected advanced solid tumors. In addition, it develops ADCT-602, which is in Phase Ia clinical trial for treatment of acute lymphoblastic leukemia; ADCT-601 and ADCT-901 that are in Phase Ia clinical trial for treatment of various solid tumors; and preclinical product candidates, including ADCT-701 and ADCT-901 for the treatment of solid tumors. It has a collaboration and license agreement with Genmab A/S, Bergenbio AS, Synaffix B.V., Mitsubishi Tanabe Pharma Corporation, Overland Pharmaceuticals, and MedImmune Limited. ADC Therapeutics SA was incorporated in 2011 and is headquartered in Epalinges, Switzerland.

    Frequently Asked Questions

    icon

    What is the current ADC Therapeutics SA (ADCT) stock price?

    ADC Therapeutics SA (NYSE: ADCT) stock price is $6.88 as of the last check on Thursday, June 23. During the trading session, ADCT stock reached the peak price of $6.9 while $6.56 was the lowest point it dropped to.

    icon

    ADCT's industry and sector of operation?

    The NYSE listed ADCT is part of Biotechnology industry that operates in the broader Health Care sector. ADC Therapeutics SA, a commercial-stage biotechnology company, develops antibody drug conjugates (ADC) for patients suffering from hematological malignancies and solid tumors. Its flagship product ZYNLONTA that is in Phase II clinical trial for the treatment of relapsed or refractory diffuse large B-cell lymphoma (DLBCL) and follicular lymphoma; Phase III clinical trial in combination with rituximab to treat relapsed or refractory DLBCL in second-line transplant-ineligible patients; and Phase I clinical trial for treatment of relapsed or refractory non-hodgkin lymphoma (NHL).

    icon

    Who are the executives of ADCT?

    Dr. Ameet Mallik
    Pres & CEO
    Mr. Michael Forer L.L.B.
    Vice Chairman, Exec. VP & Gen. Counsel
    Dr. Christopher J. Martin DPHIL, Ph.D.
    Co-Founder & Non-Exec. Director
    Ms. Jennifer Creel
    Chief Financial Officer

    icon

    What is the ADCT stock price today?

    ADCT stock traded closed the last session at $6.88, which is $0.32 or 4.88% lower than its previous close of $6.56. ADCT's current trading price is 24.64% lower than its 52-week high of $32.00 where as its distance from 52-week low of 5.52% is -78.50%.

    icon

    How many employees does ADCT have?

    Number of ADCT employees currently stands at -. ADCT operates from Biopole, Route de la Corniche 3B, Epalinges 1066, Switzerland.

    icon

    Link for ADCT official website?

    Official Webiste of $ADCT is: https://www.adctherapeutics.com

    icon

    How do I contact ADCT?

    ADCT could be contacted at ADCT operates from Biopole, Route de la Corniche 3B, Epalinges 1066, Switzerland, or at phone #41 21 653 02 00 and can also be accessed through its website.

    icon

    How many shares of ADCT are traded daily?

    ADCT stock volume for the day was 384,840 shares while in the previous session number of ADCT shares traded was 384,800 . The average number of ADCT shares traded daily for last 3 months was 243 Thousands.

    icon

    How much did ADCT change today?

    The percentage change in ADCT stock occurred in the recent session was 4.88% while the dollar amount for the price change in ADCT stock was $0.32.

    icon

    What price range ADCT stock been trading in?

    In the recent session, the day high for ADCT stock was $6.9 while the low for ADCT stock touched on the day was $6.56.

    icon

    What is the market cap of ADCT currently?

    The market value of ADCT currently stands at 495.98 Million with its latest stock price at $6.88 and 76.82 Million of its shares outstanding.